Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01491971 · ClinicalTrials.gov registry record · Phase 2
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 15
- Study locations
NCT01491971 is a Phase 2 study of Prostate Cancer that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 76 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 15 study locations across 10 states.
The verdict
NCT01491971, a Phase 2 study of Prostate Cancer, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 15
- Study locations
Study Summary
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
Conditions Studied
Interventions
- DRUG Degarelix
Study Locations (15)
Ontario
- Euroscope Inc - Barrie
- Bramalea Medical Centre - Brampton
- Urology Associates/Urologic Medical Research - Kitchener
- Office of Dr. Bernard Goldfarb - North Bay
California
- South Orange County Urology Research - Laguna Hills
- San Bernadino Urological Association - San Bernadino
Texas
- Urology Clinic of North Texas - Dallas
- Urology San Antonio Research, Pa - San Antonio
Alabama
- Urology Centers of Alabama - Homewood
Florida
- South Florida Medical Research - Aventura
New York
- Premier Medical Group of the Hudson Valley - Poughkeepsie
North Carolina
- Carolina Clinical Trials - Concord
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01491971
The ClinicalTrials.gov registry entry for NCT01491971 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Degarelix is the first listed.
NCT01491971 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Ontario, California, Texas.
Frequently Asked Questions
What is clinical trial NCT01491971 about?
NCT01491971 is a clinical study titled "Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer". Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
What is the current status of trial NCT01491971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2012-01. Estimated completion is 2012-11.
What conditions does trial NCT01491971 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01491971?
The interventions under investigation include: Degarelix (DRUG).
Who is sponsoring clinical trial NCT01491971?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01491971 being conducted?
This trial has 15 study locations across Alabama, California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.